Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem + Amox/Clav PK/WBA in Healthy Volunteers
NCT02393586Phase 1Completed
- Sponsor
- National University Hospital
- Start
- Feb 2015
- Primary completion
- Oct 2015
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of faropenem in Tuberculosis (TB) (3 arms), sponsored by National University Hospital. Primary endpoint: Cumulative Whole Blood Bactericidal Activity at 8 hours. Started Feb 2015; status: completed.
02
Drugs
faropenem
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02393586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393586.